Table 1 Overview of inclusion and exclusion criteria
Inclusion criteria | |
 1) Gestational age of 24 + 0 to < 30 + 0 weeks | |
 2) Less than 72 h old and the intention to receive the first administration of study product between 48 and 72 h after birth | |
 3) Written informed consent from custodial parent(s) | |
Exclusion criteria | |
 1) Any relevant proven or suspected chromosomal anomaly, metabolic disorder, genetic syndrome or congenital central nervous system malformation | |
 2) Presence of any gastrointestinal malformation | |
 3) No realistic prospect of survival (e.g. severe brain injury), at the discretion of the attending physician | |
 4) Concomitant participation in other intervention studies (for example, but not exclusively, those studies involving investigational or marketed nutritional or pharmaceutical products) that could impact on the main outcome parameters and/or infant safety | |
 5) Expected or foreseen inability of the infant and/or their families to adhere to protocol instructions | |
 6) Admission from an extra regional hospital, unless that hospital is a study site | |
 7) Current use of gastric acid inhibitors: H2-receptor antagonists (including ranitidine) or proton pump inhibitors (including omeprazole) |